Gene therapy is a potentially useful approach in the treatment of human brain tumors, which are notoriously refractory to conventional approaches. Most human clinical trials to date have been unsuccessful in terms of improving patient outcome. Recent improvements in viral vectors, the development of stem cell technology, and increased understanding of the mechanism of action of therapeutic transgenes provide hope that the next generation of gene therapeutics may show increased efficacy in treatment of this devastating disease.
Primary brain tumors have an incidence of around 1/10 000, the most common of which, malignant gliomas, have a dismal prognosis, with a median survival of less than 1 year. 1 Gliomas are refractory to conventional therapies, including aggressive surgical resection, radiation, and chemotherapy. Their diffuse, highly infiltrative nature precludes complete resection, leading to almost inevitable recurrence. Gene therapy is a promising alternative because gliomas consist of localized rapidly dividing cells in a background of nondividing cells, and rarely metastasize. This enables direct inoculation of the tumor, or postoperative tumor cavity, with the gene therapy agent. The large majority of studies have been carried out on malignant glioma. Despite encouraging results in animal models, clinical trials have not shown substantial therapeutic efficacy, attributed to low levels of gene transduction in patients. This review will provide an update on recent progress, which has focused on two major themes:
1. Improving gene delivery methods, and the development of new approaches such as stem cells and novel viruses. 2. Increasing transgene potency, through the use of novel transgenes, multiple transgenes, and combining transgene therapy with viral oncolysis and conventional approaches.
Advances in gene delivery methods
The aim of brain tumor gene therapy is to achieve effective therapeutic levels of transgene expression while minimizing damage to surrounding normal cells. Viral, chemical, and cell-based gene delivery strategies are under investigation (summarized in Table 1 ). Viral vectors have been considered the most effective in vivo gene delivery reagents and are extensively reviewed elsewhere. 2 Retrovirus, adenovirus, and herpes simplex virus-1 (HSV-1) are the best-studied viral brain tumor therapy vectors. These are used in replication-defective and replication-competent, tumor selective, forms. Retroviruses are usually replication-defective, and are delivered most effectively by intratumoral grafting of engineered vector producing cells (VPCs), usually fibroblasts, to produce virus in situ. 3 Strategies to improve retroviral transduction efficiency include the use of engineered replication-defective HSV-1 or adenovirus vectors to deliver retrovirus packaging sequences and transgenic DNA directly to tumor cells, converting them to VPCs, resulting in increased transgene expression in mouse tumor models. 4 An alternative approach used replication-competent retroviruses, which significantly improved infection rates in animal models compared with replication-deficient viruses, from 0.2 to 97%, with no detectable spread to nontumor tissues. 5 Adenovirus and HSV-1 are used in both replicating and replication-deficient forms. 2 Replicating strains are oncolytic, selectively lysing tumorigenic or dividing cells, thus spreading through the tumor. Several viruses have oncolytic properties, 6 and show promise in cancer therapy, particularly in brain tissue, where the majority of cells are nondividing. Furthermore, the effectiveness of tumor killing by oncolytic viruses can be enhanced by the incorporation of therapeutic transgenes.
Oncolytic adenovirus tumor selectivity is achieved through deleting specific viral genes. Mutations in E1A allow selective replication in cells with defects in the retinoblastoma (RB) tumor suppressor pathway. 7 Loss of functional E1B prevents late viral RNA export, which is complemented by tumor cells, 8 and does not target cells with mutated p53 as originally proposed. 9 Oncolytic adenoviruses are effective in experimental gliomas -ONYX-015 (deleted in E1B) potentiated radiotherapy in human primary glioma xenografts, 10 and has shown efficacy in clinical trials when combined with chemotherapy. 11 An adenovirus mutated in both E1A and E1B had potent antitumor effects in intracranial D-54 MG glioma xenografts, with increased tumor selectivity. 12 HSV-1 has natural tropism for neurons, and oncolytic variants replicate selectively in mitotic cells through deletion of genes that normally increase nucleotide bioavailability in infected quiescent cells. 13 Other deletions reduce neurovirulence (ICP34.5) and improve antigen presentation (ICP47). 14 The engineering of improved viral gene therapy vectors is an ongoing process and may be essential in order to achieve clinical efficacy. Tumor selectivity can be improved using glioma-selective promoters 6 to drive expression of viral proteins, or transgenes. For example, using the nestin promoter to drive expression of ICP34.5 in oncolytic HSV-1 strongly enhanced antiglioma effects, even in well-established human U87 intracranial tumors in mice. 15 Adenoviruses enter cells through the cocksackievirus and adenovirus receptor (CAR), which is often downregulated in gliomas. Redirection of adenovirus towards tumor cells by modification of capsid proteins can increase infection rates. Strategies include antibodymediated redirection to cell surface receptors overexpressed in gliomas. Incorporation of the integrin binding arg-gly-asp (RGD) motif resulted in complete glioma regression in nine of 10 mice. 16 Other viruses under investigation include adeno-associated virus (AAV), which penetrates solid tumors effectively, and triggers death of cells with disrupted p53, because the structure of its DNA elicits a DNA damage response. 17 Several other viruses are emerging as possible gene delivery agents, 6 including parvovirus H1 18 and measles virus. 19 Fusogenic membrane proteins expressed by measles and other viruses can enhance oncolytic viral therapy by causing massive syncytia formation followed by cell death in tumor models, and are being increasingly explored as antitumor transgenes. 20 Methods such as electroporation and lipofection offer a simpler alternative to viral methods but have suffered due to low transfection efficiencies in vivo. Nonetheless, cationic liposomes have been used to deliver therapeutic genes in a human brain tumor trial. 21 Successful gene delivery using immunoliposomes specifically targeted to glioma cells with monoclonal antibodies has been reported. 22 Finally, there are occasional examples of the use of naked plasmid DNA in brain tumor gene therapy. 23 Cellular gene delivery methods are gaining importance because of the emerging utility of neural stem cells (NSCs). 24 NSCs are tolerated by the immune system, have and endothelial progenitor cells. 28 This encouraging data suggests that stem cell-based therapeutics will become increasingly prominent as an alternative to viral gene delivery systems, and also have been used to improve viral gene delivery. 29 
Increasing transgene effectiveness in brain tumor gene therapy
Transgenes under investigation for brain tumor therapy include prodrug activating genes, intracellular signaling molecules, immune modulators, and inhibitors of angiogenesis and cell invasion. Much recent work has gone into increasing our understanding of the mechanisms of action of various potential therapeutic approaches in order to increase their effectiveness in a clinical setting. This section will focus on new developments in these areas.
Prodrug activating, or 'suicide' genes provide an elegant approach to cancer treatment. These metabolize harmless prodrugs into locally concentrated toxic metabolites, avoiding the systemic effects of toxic drug administration (reviewed in Vassaux and MartinDuque 30 ). An important feature of prodrug therapy is the 'bystander effect' allowing killing of nontransduced cells by the passage of toxic metabolites from neighboring cells. In addition, these approaches can stimulate antitumor immune responses. 31 This strategy has been well studied, but clinical data obtained so far suggests that improvements are required for therapeutic efficacy. Recent improvements outlined below suggest that improved therapeutic strategies will be forthcoming.
The HSV-1 thymidine kinase/ganciclovir (TK/GCV) system is the best studied of these methods. TK/GCV efficacy in animal models has been repeatedly demonstrated using viral delivery, has antiangiogenic effects through toxicity towards endothelial cells around the tumor, and led to increased radiation sensitivity of human glioblastoma xenografts in an athymic mouse model. 32 Strategies to improve therapy include optimizing delivery regimens, the timing of gene and drug delivery being a crucial factor in therapeutic success. 33 TK with increased enymatic activity, generated by mutagenesis, enhanced GCV sensitivity in flank tumor models, 34 and new GCV formulations with improved bioavailability are in development. 35 The TK bystander effect is enhanced by gap junctions, and codelivery of the gap junction protein connexin-43 synergistically increased effectiveness. An adenoviral vector expressing TK, connexin-43, and tumor-necrosis factor-alpha (TNF-a) caused a high level of tumor ablation in conjunction with radiotherapy in an immunocompetent rat model. 36 Cytosine deaminase (CD) in combination with 5-fluorocytosine (5-FC) improved the efficiency of tumor killing by oncolytic adenovirus in intracranial U87 xenografts, 37 and using replicationcompetent retrovirus resulted in 100% survival over a 60-day follow-up period. 5 Escherichia coli purine nucleoside phosphorylase (PNP), which can be used in conjunction with a number of prodrugs, generates toxic membrane permeant metabolites with high bystander activity, which can target both dividing and nondividing cells within the tumor. In subcutaneous glioma models, adenoviral PNP delivery was effective even when over 95% of the tumor mass was composed of bystander cells. 38 Other effective enzyme/ prodrug combinations include rat cytochrome P450/ cyclophosphamide (CPA), carboxylase/CPT11, and uracil phosphoribosyl transferase/5-fluorouracil (UPRT)/5-FU.
Improved efficacy has been observed by combining prodrug therapies. For example, simultaneous adenoviral delivery of UPRT/5FU and TK/GCV to experimental gliomas was more effective than either therapy alone, and was further enhanced by local radiotherapy, resulting in 90-100% survival. 39 Recently, stem cells have been used to deliver prodrug-converting enzymes, 40, 41 and transduction efficiency of replication-conditional HSV1 vectors expressing cytochrome P450 was much enhanced using neural precursor cells. 29 Improvements to overcome the limitations of low transduction levels in patients may be gained by combining prodrug therapies with other transgenic approaches, for example by recruiting the immune response, as outlined below.
Escape from immune surveillance is vital to tumor progression. Using the immune system to attack tumors shows great promise, because a vigorous antitumor immune response will lead to its complete eradication, including the clearance of all tumor foci (reviewed in Ehtesham et al. 42 and Okada and Pollack
43
). Cytokines are key immunoregulators and have shown efficacy in experimental animal tumor models. Gene therapy is attractive because direct systemic administration of cytokines is limited by half-life and may cause toxicity. A wide-range of cytokines have been successfully used in experimental brain tumor models. The best studied are the interleukins, IL-2, IL-4, and IL-12, the interferons, IFN-a, IFN-b, and IFN-g, as well as TNF-a and granulocyte macrophage-stimulating factor (GM-CSF). As well as stimulating the immune system by various mechanisms, these factors can promote apoptosis (IFN-b and TNF-a) and can be antiangiogenic (IL-12 and IFN-a). Cytokine genes can be directly transduced into tumor cells, or used to enhance tumor vaccination strategies. A large number of studies have demonstrated the effectiveness of immunostimulatory cytokine gene delivery, which can inhibit experimental rodent brain tumor growth, and establish protective immunity. 42, 43 Effective delivery of cytokines to brain tumors has been reported using a wide variety of viral vectors, liposomes, and stem cells. Engineered mouse primary progenitor cells could release high levels of IL-4 protein and exhibited a strong antitumor effect in either mouse GL261 or rat C6 glioma cells in syngeneic models, 44 and IL12 secreting neural stem cells effectively decrease intracranial tumor size. 45 Other strategies include downregulation of immunosuppressants such as TGF-b by RNAi 46 and the use of costimulatory molecules to improve antigen presentation. 47 Cytokines can enhance the effects of oncolytic HSV-1, 48 and are effective when used in combination (e.g., Liu et al. 49 ). IL-12 enhanced CD/5FC therapy, 50 and IL-2 combined with TK/GCV has been used in human trials. 51 Vaccination using whole tumor cell inoculation can be potentiated by engineering irradiated tumor cells to secrete immunostimulatory cytokines such as GM-CSF, 52 leading to protective immunity in animal models. In addition, GM-CSF, IL-4, and IL-12 secreting vaccines showed strong synergy with local tumor irradiation. 53 Dendritic cells (DCs), the most potent known antigenpresenting cells, are used in tumor vaccination strategies after pulsing with tumor lysates. 43 DC therapy may be improved by simultaneous transduction of mouse intracranial glioma cells with cytokines such as IFN-b. 54 Adenoviral transduction of human soluble FMS-like ligand (hsFLT3L) -a potent DC differentiation and proliferation factor -led to recruitment of DC-like cells, and long survival periods, with elimination of intracranial gliomas in rats. 55 Some potential difficulties may arise in cytokine gene therapy because expression levels need to be within a certain range for effectiveness. Also, the antigenic heterogeneity of tumors may lead to the emergence of resistant clones. Further understanding of the complex tumor/immune system interactions may lead to further breakthroughs and novel approaches in this area.
A variety of cell signaling pathways have been targeted in glioma therapy. Oncogenes, tumor suppressors, and apoptotic regulators all contribute to gliomagenesis, providing a rich source of potential therapeutic targets. 56 Amplification of epidermal growth factor receptor (EGFR) signaling occurs in many brain tumors. Retroviral transduction of a dominant negative EGFR radiosensitized glioma models. 57 EGFR knockdown by RNAi, delivered intravenously using immunoliposomes led to 95% suppression of EGFR function and increased survival of mice with advanced intracranial gliomas. 22 Allele-specific RNAi effectively suppresses the mutant EGFRVIII allele in cell lines. 58 Other potential oncogenic targets in gliomas include PDGFR and downstream signaling molecules, particularly the Akt pathway.
The Akt kinase promotes cell survival and is constitutively active in many gliomas due to downregulation of the PTEN tumor suppressor. Adenoviral delivery of PTEN to deficient glioma cells inhibited Akt and induced cell death. 59 PTEN and p53 cause radiodensitization and have a bystander effect through angiogenesis inhibition. 60 Tumor suppressor gene therapy is viewed as an exciting prospect because expression in defective cells can cause cell death, with limited effects on normal cells (reviewed in McNeish et al.
61
). Transduction of p53 induces apoptosis in glioma cells with p53 mutations, whereas cells expressing wild-type p53 undergo growth arrest. p53 enhanced the effects of an oncolytic adenovirus, with lengthy survival times in animal models. 62 Other tumor suppressor genes, which act in a p53-independent fashion, may prove to be more effective than p53. For example, melanoma differentiation-associated gene-7 (mda7/IL-24) is a tumor suppressor that causes apoptosis in cancer cells, is in clinical trials for melanoma, and caused glioma cell apoptosis and radiosensitization, independent of cellular p53 status. 63 There are many reports of the delivery of apoptosisinducing transgenes to cancer cells (reviewed in Shinoura and Hamada 64 and Reed 65 ). Proapoptotic genes can cooperate (e.g. with p53), and radiosensitize cells. Combining delivery of the cell death activator BimS with TK/GCV suicide therapy showed enhanced antiglioma effects. 66 The use of secreted apoptosis-inducing ligands such as FasL and TRAIL allows an effect even when lower numbers of cells are transduced, and can be delivered using ex vivo transduced stem cells. 67 An alternative approach is the inhibition of antiapoptotic molecules. Adenoviral delivery of RNAi to knockdown the antiapoptotic molecule survivin suppressed growth in U251 glioma xenografts. 68 The targeting of intracellular signaling pathways may present some challenges, particularly the need for high transduction levels. Also, because these pathways are not fully understood, and often multifunctional, there may be unanticipated effects of transgene expression. Critically, cellular responses can depend on the level of transgene expression, which must be controlled appropriately.
Glioblastoma multiforme (GBM) is one of the most highly vascularized human neoplasms and is an attractive candidate for antiangiogenic therapy. 69 Angiogenesis is essential for brain tumor growth beyond 2-3 mm is size, and correlates with tumor grade. VEGF is the most potent proangiogenic molecule, and signaling can be disrupted by viral delivery of dominant negative VEGF receptors, blocking brain tumor growth in glioma xenografts. 70 A novel approach was recently described in which stable expression of the FMS-like tyrosine kinase receptor delivered by AAV effectively blocked angiogenesis in ovarian cancer xenografts by sequestering both VEGF and VEGFR. 71 Angiostatin and endostatin have potent antiangiogenic properties in vivo. A recent study demonstrated better long-term efficacy compared with either gene alone when codelivered by AAV to mouse tumor xenografts. 72 Additionally, intratumoral or intramuscular angiostatin delivery by AAV led to long-term survival, increased further by TK/GCV therapy for intratumorally treated mice. 73 When endostatin was delivered in the form of naked plasmid DNA injected intra-arterially, transgene expression was seen in brain tumors, enhancing survival time by up to 47% in a rat syngeneic brain tumor model. 23 Extensive tumor invasion is highly characteristic of brain tumors, and represents a major therapeutic challenge. Invasion involves extracellular matrix modification by proteases and protease inhibitors, cytoskeletal reorganization, growth factors, cytokines, and intracellular signaling molecules. 74 The expression of matrix metalloproteinases (MMPs) is radically altered in migrating brain tumor cells, and invasion is suppressed by tissue inhibitor of matrix metalloproteinase 2 (TIMP2) and PTEN, which inhibits MMP2 secretion. Adenoviral delivery of PTEN and TIMP2 led to inhibition of U87 cell migration in vitro. 75 Urokinase-type plasminogen activator (uPAR) plays a key role in tumor progression by virtue of its ability to initiate a cascade of proteases. Interference with this pathway using antisense or RNAi may represent a useful approach. 74 Pigment epithelium-derived factor (PEDF) is antiangiogenic, and also inhibited invasion and growth of U251 glioma cell xenografts, potentially through downregulation of MMP9 expression. 76 Brain tumor gene therapy clinical trials Human brain tumor gene therapy trials carried out to date are summarized in Table 2 . These are mostly performed following tumor resection in patients with recurrent GBM. The first human glioma trials involving gene therapy used VPCs to produce TK-expressing retroviruses in situ, followed by GCV administration. Initial studies, carried out on small patient numbers, showed that the treatment was well tolerated, with some extended recurrence free periods. Another small trial used retroviral delivery of both IL-2 and HSV-tk to treat four patients, with survival of 12 months reported for two patients. 51 The first randomized controlled phase III gene therapy trial was carried out using TK/GCV therapy in 248 newly diagnosed GBM patients, treated with VPC injection following surgical tumor resection, with subsequent GCV administration and radiotherapy. Survival analysis showed no significant differences in time to progression or overall survival time between treated and control groups. 77 The main reason for lack of efficacy was thought to be poor efficiency of retroviral infection of glioma cells in vivo.
A comparative study demonstrated higher patient survival using adenovirus delivery of TK than with retroviral vectors. 78 A randomized controlled study of adenovirus TK/GCV therapy has recently been reported using 36 patients. This was carried out using between 30 and 70 injections around the tumour cavity to target infiltrating tumor cells. Extended median survival from 38 weeks to 72 weeks was reported. 79 One report of tumor suppressor gene therapy for malignant gliomas has been published. 80 Adenovirusmediated delivery of p53 to 15 patients diagnosed with recurrent GBM showed no evidence of efficacy. The results of most clinical studies have not lived up to the expectations created by experimental data, although the recent data from adenoviral TK are encouraging. 79 The inability to infect large numbers of tumor cells, and the limited spread of vector within the tumor mass contribute to the poor results. This was seen in the p53 trial, where p53 transduction was seen immediately adjacent to the needle tract, but not at a distance, 80 and in other studies, which showed retrovirally delivered TK activity limited to VPCs, with infection rates of only 0.17% 81 and 0.01-4% with adenovirus. 82 A recent report described the wide variability of infectivity of primary brain tumor cultures using replication-deficient HSV-1 amplicons, which may explain the different responsiveness of patients to virotherapy. 83 Potential solutions include the use of oncolytic vectors that can propagate throughout the tumor mass.
Several trials have been reported using oncolytic viruses. Studies using oncolytic HSV-1 deleted in ICP34.5 showed the vector was well tolerated, with evidence of viral replication in tumor tissue, and some extended patient survival. 84 G207, an HSV-1 strain doubly mutated in ICP34.5 and ribonucleotide reductase genes, was well tolerated in a phase I trial, with two out of 21 patients alive 4 years after treatment. 85 The first oncolytic adenovirus to enter a clinical trial for malignant glioma was ONYX-015. 86 Trials involving over 300 patients, established the safety of this approach, and demonstrated selective activity within malignant tissue, although significant clinical benefit was not seen in the majority of patients. However, ONYX-015 did show efficacy when combined with chemotherapy in head and neck cancer, 11 suggesting that combinatorial therapies may also be more effective in glioma therapy.
Other strategies tested in clinical trials include IFN-b delivery using cationic liposomes. 21 Five patients with GBM or anaplastic astrocytoma were treated, transgene expression was detected in four patients, and two patients showed over 50% reduction in tumor size with two other patients stable 10 weeks after therapy.
The advances in basic research outlined in the previous sections should provide new tools and strategies to improve the outcome of these clinical trials.
Conclusions
Brain tumor gene therapy has shown promise in animal model studies. Although gene delivery to human patients appears to be safe, these studies have not yet translated to benefits in the clinic. However, they have provided a wealth of experimental data demonstrating proof of concept. The challenge is to translate this knowledge into effective therapies for human patients. A major concern is that tumors in animal models are highly idealized, forming well-circumscribed tumors, and while useful clearly do not fully replicate the biology of established human brain tumors, which are heterogenous, highly infiltrative, and have developed over long periods of time.
Some recently developed models lead to a more invasive phenotype, either by intracranial implantation of spheroids derived from brain tumor biopsies into nude rats, 87 or by maintaining human GBM biopsies as flank tumors in nude mice prior to intracranial xenografting. 88 The use of such models will provide a more useful basis for the development of successful therapeutic strategies.
Recent advances in several areas of the biological sciences will continue to have a high impact on this area:
1. Data from the human genome sequencing project will allow the identification of novel gene therapy candidates, and will also lead to more accurate tumor classification, and tumor-specific treatments. 2. Noninvasive imaging techniques will play a major role in the in vivo study of experimental tumors in animals and patients, allowing continuous quantitative monitoring. 89 3. The use of three-dimensional neuronavigation techniques and automated slow speed injection/infusion devices such as convection enhanced delivery, to allow continuous injection into the tumor may improve the dispersal of gene delivery vectors around the tumor site. 90 4. The continued discovery and development of new technologies, such as RNAi and stem cells, are providing tools to explore novel therapeutic strategies.
The recent clinical study demonstrating statistically relevant clinical success using adenovirus to deliver TK 79 provides hope that gene therapy can be used to improve the outlook for brain tumor patients. Combining this strategy with some of the experimental approaches outlined in this article (e.g. vector retargeting, immune gene therapy, and radiotherapy) could lead to further clinical benefits.
Many challenges still remain, including our incomplete understanding of the complex biological systems involved, and inherent glioma heterogeneity and invasiveness, along with low levels of gene transduction in patients. Recent experimental progress in gene delivery methods and combined treatments suggests that continued aggressive research in these areas could ultimately provide a diverse group of therapeutic agents, tailored to specifically treat a range of brain tumor types.
